Pubblicazioni

Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

2022 - THE LANCET. HAEMATOLOGY

Dimopoulos, Meletios A; Richardson, Paul G; Bahlis, Nizar J; Grosicki, Sebastian; Cavo, Michele; BeksaÃ§, Meral; LegieÄ, Wojciech; Liberati, Anna M; Goldschmidt, Hartmut; Belch, Andrew; Magen, Hila; Larocca, Alessandra; Laubach, Jacob P; Petrucci, Maria T; Reece, Donna; White, Darrell; Mateos, MarÃa-Victoria; Å piÄka, Ivan; Lazaroiu, Mihaela; Berdeja, JesÃºs; Kaufman, Jonathan L; Jou, Ying-Ming; Ganetsky, Alex; Popa McKiver, Mihaela; Lonial, Sagar; Weisel, Katja; Martelli, Maurizio

IgD Subtype But Not IgM or Non-Secretory Is a Prognostic Marker for Poor Survival Following Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Results From the EBMT CALM (Collaboration to Collect Autologous Transplant Outcomes in Lymphomas and Myeloma) Study

2021 - CLINICAL LYMPHOMA MYELOMA & LEUKEMIA

Lawless, S; Sbianchi, G; Morris, C; Iacobelli, S; Bosman, P; Blaise, D; Remenyi, P; Byrne, Jl; Mayer, J; Apperley, J; Lund, J; Kobbe, G; Schaap, N; Isaksson, C; Lenhoff, S; Basak, G; Touzeau, C; Wilson, Kmo; Muniz, Sg; Scheid, C; Browne, P; Anagnostopoulos, A; Rambaldi, A; Jantunen, E; Kroger, N; Schonland, S; Yakoub-Agha, I; Garderet, L

Diffusion-weighted whole-body MRI for evaluation of early response in multiple myeloma

2017 - CLINICAL RADIOLOGY

Lacognata, C.; Crimi, F.; Guolo, A.; Varin, C.; De March, E.; Vio, S.; Ponzoni, A.; Barila, G.; Lico, A.; Branca, A.; De Biasi, E.; Gherlinzoni, F.; Scapin, V.; Bissoli, E.; Berno, T.; Zambello, R.